Profiling the bacterial content and its ratio in the human gut have led to the development of several therapeutic strategies such as probiotics, and also therapeutic improvements such as the case of CTLA‐4‐based cancer immunotherapy (Vétizou et al., 2015). The gene discussed is CTLA4; the disease is cancer.